Caspase Inhibitor Enters Clinical Trial In Islet Transplantation As Treatment For Diabetes
10:05 EDT 19 Jul 2012 | PR Newswire
This article has expired, however you can still
download the PDF.
Preview:
SAN DIEGO and EDMONTON, Alberta, July 19, 2012 /PRNewswire/ -- Conatus Pharmaceuticals Inc. and the University of Alberta announced today the treatment of the first patient in an investigator-initiated islet cell transplant Phase I/II trial of ...
Other Sources for this Article
More From BioPortfolio on "Caspase Inhibitor Enters Clinical Trial In Islet Transplantation As Treatment For Diabetes"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
